Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Xbrane Biopharma AB ( (SE:XBRANE) ) has issued an update.
Xbrane Biopharma has commissioned life science specialist Venture Valuation to provide an external valuation of Xdivane, its nivolumab biosimilar program, tied to an existing license agreement. The independent analysis estimates a pre-tax net present value of about SEK 4.4 billion for Xbrane at launch, based on roughly SEK 9.6 billion in accumulated profit sharing over the first 10 years from commercialization.
The valuation assumes Xdivane secures early biosimilar entry in the PD-1 inhibitor market, with U.S. approval expected in late 2028 and EU approval in 2030. Using assumptions on market size, biosimilar uptake, pricing trends, and a 20% share of the nivolumab IV biosimilar segment, the assessment underscores the potential financial significance of Xdivane for Xbrane’s long-term growth and its positioning in the high-value oncology biosimilars space.
More about Xbrane Biopharma AB
Xbrane Biopharma AB is a Sweden-based biotechnology company that develops biological drugs using a patented platform designed to lower production costs versus competing systems. The company focuses on a portfolio of biosimilar candidates targeting reference products with an estimated EUR 23 billion in combined annual peak sales, led by its eye drug Ximluci, which received European market authorization and was launched in 2023.
Average Trading Volume: 62,502
Technical Sentiment Signal: Sell
Current Market Cap: SEK226.7M
For detailed information about XBRANE stock, go to TipRanks’ Stock Analysis page.